Olukemi Fajolu, MD
Hand Surgery · Vestal, NYNPI 1023268620
Payments from drug & device makers
What this record shows
This record is dominated by grants: $10,000 of the $15,571 with a category attached, or 64.2%. Arthrex accounts for 70.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $11,734 and has fallen 95.2% since, to $569 in 2025.
Across 31 payments — averaging $502.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$11K
- FX Shoulder Solutions, Inc$2K
- MVP Orthopedics Inc$1K
- Axogen$1K
- Coastal Medical Technologies LLC$252
- Vertex$86
- plus $262 from 7 others
What the payments were for
- Grants$10,00064%
- Travel & lodging$2,01313%
- Food & beverage$1,89012%
- Education$1,66811%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 14 | $11,004 |
| FX Shoulder Solutions, Inc | 2 | $1,728 |
| MVP Orthopedics Inc | 2 | $1,210 |
| Axogen | 2 | $1,028 |
| Coastal Medical Technologies LLC | 3 | $252 |
| Vertex | 1 | $86 |
| Medical Device Business Services, Inc. | 1 | $84 |
| Stryker | 1 | $58 |
| Prodigy Surgical Distribution, Inc. | 1 | $28 |
| Acell, Inc. | 1 | $26 |
| Smith+Nephew | 1 | $25 |
| Acumed LLC | 1 | $22 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AxoGuard Nerve Connector$1,028
- AxoGuard Nerve Protector$1,028
How this compares
$15,571 in reported general payments places this provider in the 80th percentile of 178 hand surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylprednisolone | 25 | $185 |
| Doxycycline Monohydrate | 11 | $150 |
Paid to pharmacies, not to this prescriber.
Other hand surgery in Vestal
- Scott WolfeNy$251K
- Nader PaksimaNew York$171K
- Peter SteinGreat Neck$131K
- Michael HausmanNew York$128K
- Otis BarronNew York$122K
- Kevin SetterEast Syracuse$118K
- Nathan EverdingSyracuse$98K
- David TuckmanGreat Neck$96K
- Dan ZlotolowNew York$91K
- Andrew GreenbergGreat Neck$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.